Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | BCL2 | P10415 | 2/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29922027 | 1.00 | ROCK2 (0.34) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL7917122 | 0.99 | ROCK2 (0.34) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL7913240 | 0.95 | ROCK2 (0.34) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL7911578 | 0.93 | BCL2 (0.35) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL7911557 | 0.93 | FFAR1 (0.35) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL7903224 | 0.93 | CYP19A1 (0.34) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL7917118 | 0.93 | ROCK2 (0.34) | ROCK2TP53SMN1; SMN2ITGB3ITGA2B | |
| SCHEMBL7913269 | 0.91 | ROCK2 (0.34) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL3209182 | 0.87 | FFAR1 (0.34) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL795594 | 0.87 | ROCK2 (0.34) | ROCK2TP53PKMNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-08-18 | — | — | US | disclosed |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-02-03 | — | — | US | disclosed |
| US-20100040666-A1 | Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent | TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100040666-A1 | Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent | TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-19 | — | — | US | disclosed |
| US-6291485-B1 | TREATMENT OF POST-PTCA RESTENOSIS | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-1002797-A1 | 4,5-DIHYDRO- 1H]-BENZ g]INDAZOLE-3-CARBOXYLIC ACID DERIVATIVES | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2000-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100040666-A1 | Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent | EDNRB, EDNRA, EPHB2 | ROCK2 964/4885TP53 4737/4885PKM 3262/4885 |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | ROCK2 2882/4885TP53 4842/4885PKM 872/4885 |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | ROCK2 1392/4885TP53 723/4885PKM 3228/4885 |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADORA2A, PDE4A, PDE4D | ROCK2 662/4885TP53 930/4885PKM 2122/4885 |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | ROCK2 1392/4885TP53 723/4885PKM 3228/4885 |
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADRB1, ADRB2, ADRA2B | ROCK2 674/4885TP53 2817/4885PKM 4001/4885 |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | BCL6, BCL6B, BCL3 | ROCK2 395/4885TP53 703/4885PKM 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.